CDNA

CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.

CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and positive net income, with strong guidance for 2026.

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026. Naveris's lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — in.

The CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average of around $24.03 per share on June 15. The transaction represented 2.7% of John Hanna's direct holdings.

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced its participation at the American Transplant Congress (ATC) 2026, taking place June 20–24 in Boston, Massachusetts. Real-world clinical use and scientific advancements involving AlloSure® Kidne.

CareDx NASDAQ: CDNA executives outlined the company's strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion.

CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,.

CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript